Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 54Gastrointestinal 8Thoracic 7Gynecologic 6Head & Neck 4Genitourinary 3Sarcoma 2Plasma cell 1Other solid neoplasm 1Lymphoid 1

Conditions

Sarcoma 63Osteosarcoma 16Leiomyosarcoma 16Neoplasm Metastasis 10Pancreatic Neoplasms 9Breast Neoplasms 9Bone Neoplasms 8Rhabdomyosarcoma 6Ovarian Neoplasms 6Neoplasms 6Colorectal Neoplasms 6Small Cell Lung Carcinoma 5Sarcoma, Ewing 5Liposarcoma 5Head and Neck Neoplasms 5Colonic Neoplasms 5Sarcoma, Synovial 4Prostatic Neoplasms 4Melanoma 4Histiocytoma, Malignant Fibrous 4Hemangiosarcoma 4Chondrosarcoma 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Recurrence 3Lymphoma, Non-Hodgkin 3Lung Neoplasms 3Gastrointestinal Stromal Tumors 3Esophageal Neoplasms 3Dermatofibrosarcoma 3

Interventions

pembrolizumab 7Cyclophosphamide 6Nivolumab 4fludarabine 3spartalizumab 2aldesleukin 2Trastuzumab 2Standard of Care 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Irinotecan 2Ipilimumab 2Gemcitabine 2zanidatamab 1vocimagene amiretrorepvec 1veliparib 1tucatinib 1trilaciclib 1trebananib 1trastuzumab duocarmazine 1toripalimab 1tislelizumab 1tinostamustine 1talazoparib 1sarilumab 1sargramostim 1regorafenib 1pexidartinib 1pertuzumab 1pegfilgrastim 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Gemcitabine × Sarcoma × Clear all
NCT02632448 2025-05-02

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer

Esperas Pharma Inc.

Phase 1/2 Completed
229 enrolled
BreastGastrointestinalGynecologicSarcoma

Breast Neoplasms, Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Recurrence, Sarcoma, Colorectal Neoplasms, Endometrial Neoplasms, Gastrointestinal Stromal Tumors, Triple Negative Breast Neoplasms

NCT03997968 2024-12-24

A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors

Cyteir Therapeutics, Inc.

Phase 1/2 Completed
169 enrolled
BreastGastrointestinalGynecologicHead & NeckLymphoidPlasma cellSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Head and Neck Neoplasms, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Lymphoma, Mantle-Cell, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡